Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #40 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Concord Biotech Limited (this stock) | 14,185 | 50.3 | 12.9% | -16.3% | 0.56% | 69 | 0 | 30 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 257 | 77 | 58 | ₹ |
| March 31, 2026 | 326 | 114 | 88 | ₹ |
| Dec. 31, 2025 | 278 | 87 | 64 | ₹ |
| Sept. 30, 2025 | 247 | 83 | 63 | ₹ |
| June 30, 2025 | 204 | 57 | 44 | ₹ |
| March 31, 2025 | 430 | 185 | 140 | ₹ |
| Dec. 31, 2024 | 244 | 99 | 76 | ₹ |
| Sept. 30, 2024 | 310 | 133 | 96 | ₹ |
| June 30, 2024 | 216 | 78 | 60 | ₹ |
| March 31, 2024 | 319 | 131 | 95 | ₹ |
| Dec. 31, 2023 | 241 | 100 | 78 | ₹ |
| Sept. 30, 2023 | 262 | 113 | 81 | ₹ |
| June 30, 2023 | 195 | 65 | 54 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 1,055 | 342 | 259 |
| March 31, 2025 | 1,200 | 496 | 372 |
| March 31, 2024 | 1,017 | 409 | 308 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 267 | -143 | -113 | 95 | 172 |
| March 31, 2025 | 245 | -160 | -99 | 111 | 133 |
| March 31, 2024 | 265 | -155 | -99 | 86 | 180 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 2,235 | 2,015 | 2,007 | 0 | 0 | 1,250 | 169 | 12 | 786 | 326 |
| March 31, 2025 | 2,034 | 1,813 | 1,802 | 0 | 0 | 1,135 | 184 | 1 | 792 | 240 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
